In this timely episode of The Glioblastoma AKA GBM Podcast, released just after Glioblastoma Awareness Day, we welcome John Furey, the CEO of Imvax, Inc. John discusses the groundbreaking work of Imvax, particularly their lead product candidate, IGV-001, currently in a phase 2b randomized trial for newly diagnosed glioblastoma multiforme (GBM). He shares insights into the unique challenges and opportunities of developing patient-specific vaccines and immunotherapy strategies in the fight against GBM. The conversation also delves into the broader landscape of clinical trials, highlighting how these innovative approaches are transforming patient care and outcomes in oncology. Join us to understand more about the cutting-edge science that could potentially revolutionize treatment for glioblastoma and beyond.

Episode Sponsor: IMVAX. Visit https://www.imvax.com/ to learn more.

Trigger Warning: This episode includes discussions on medical conditions and cancer treatments.

Visit to Learn More: For more information and support resources, visit GBMResearch.org.

Disclaimer: The content discussed on The Glioblastoma AKA GBM Podcast is based on personal stories and experiences. It is not intended as medical advice. Always consult with healthcare professionals for medical guidance and treatment options.